Literature DB >> 7644863

An alternative approach to the optimal design of an LD50 bioassay.

R A Markus1, J Frank, S Groshen, S P Azen.   

Abstract

In this paper we propose an alternative approach to the optimal design of an LD50 bioassay. We adopt a Bayesian approach to make use of prior information about the location and scale parameters of the tolerance distribution function to select the design parameters (number of doses, total number of animals, centre of doses, space between doses), and we adopt a frequentist approach using the Spearman-Karber statistic to estimate the LD50. We define the optimal design as the one that produces the minimum expected mean squared error E(MSE) with respect to the joint prior distribution of the parameters of the tolerance distribution. For the design parameters investigated, we found: (i) the shape of the E(MSE) is relatively smooth and continuous, the magnitude of which is influenced by the underlying tolerance distribution; (ii) the amount of prior information about the location and scale parameters independently and jointly affect the optimal design; and (iii) as the amount of prior information decreases, one requires more doses and/or animals. Finally, we show the proposed method is robust for an incorrectly assumed tolerance distribution function.

Entities:  

Mesh:

Year:  1995        PMID: 7644863     DOI: 10.1002/sim.4780140812

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  PrP expression level and sensitivity to prion infection.

Authors:  Jean-Yves Douet; Caroline Lacroux; Fabien Corbière; Claire Litaise; Hugh Simmons; Séverine Lugan; Pierrette Costes; Hervé Cassard; Jean-Louis Weisbecker; François Schelcher; Olivier Andreoletti
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

2.  The emergence of classical BSE from atypical/Nor98 scrapie.

Authors:  Alvina Huor; Juan Carlos Espinosa; Enric Vidal; Hervé Cassard; Jean-Yves Douet; Séverine Lugan; Naima Aron; Alba Marín-Moreno; Patricia Lorenzo; Patricia Aguilar-Calvo; Juan Badiola; Rosa Bolea; Martí Pumarola; Sylvie L Benestad; Leonore Orge; Alana M Thackray; Raymond Bujdoso; Juan-Maria Torres; Olivier Andreoletti
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

3.  Prion potentiation after life-long dormancy in mice devoid of PrP.

Authors:  Davy Martin; Fabienne Reine; Laetitia Herzog; Angélique Igel-Egalon; Naima Aron; Christel Michel; Mohammed Moudjou; Guillaume Fichet; Isabelle Quadrio; Armand Perret-Liaudet; Olivier Andréoletti; Human Rezaei; Vincent Béringue
Journal:  Brain Commun       Date:  2021-04-28

4.  Atypical/Nor98 scrapie infectivity in sheep peripheral tissues.

Authors:  Olivier Andréoletti; Leonor Orge; Sylvie L Benestad; Vincent Beringue; Claire Litaise; Stéphanie Simon; Annick Le Dur; Hubert Laude; Hugh Simmons; Séverine Lugan; Fabien Corbière; Pierrette Costes; Nathalie Morel; François Schelcher; Caroline Lacroux
Journal:  PLoS Pathog       Date:  2011-02-10       Impact factor: 6.823

5.  Highly efficient prion transmission by blood transfusion.

Authors:  Olivier Andréoletti; Claire Litaise; Hugh Simmons; Fabien Corbière; Séverine Lugan; Pierrette Costes; François Schelcher; Didier Vilette; Jacques Grassi; Caroline Lacroux
Journal:  PLoS Pathog       Date:  2012-06-21       Impact factor: 6.823

6.  Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy.

Authors:  Y R Parma; P A Chacana; A Rogé; A Kahl; A Cangelosi; P Geoghegan; P M A Lucchesi; M E Fernández-Miyakawa
Journal:  Toxicon       Date:  2011-07-22       Impact factor: 3.033

7.  Wide distribution of prion infectivity in the peripheral tissues of vCJD and sCJD patients.

Authors:  Jean-Yves Douet; Alvina Huor; Hervé Cassard; Séverine Lugan; Naima Aron; Mark Arnold; Didier Vilette; Juan-Maria Torres; James W Ironside; Olivier Andreoletti
Journal:  Acta Neuropathol       Date:  2021-02-02       Impact factor: 17.088

8.  Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease.

Authors:  Jean Yves Douet; Saima Zafar; Armand Perret-Liaudet; Caroline Lacroux; Séverine Lugan; Naima Aron; Herve Cassard; Claudia Ponto; Fabien Corbière; Juan Maria Torres; Inga Zerr; Olivier Andreoletti
Journal:  Emerg Infect Dis       Date:  2014-01       Impact factor: 6.883

9.  Prions from Sporadic Creutzfeldt-Jakob Disease Patients Propagate as Strain Mixtures.

Authors:  Hervé Cassard; Alvina Huor; Juan-Carlos Espinosa; Jean-Yves Douet; Severine Lugan; Naima Aron; Didier Vilette; Marie-Bernadette Delisle; Alba Marín-Moreno; Patrice Peran; Vincent Beringue; Juan Maria Torres; James W Ironside; Olivier Andreoletti
Journal:  mBio       Date:  2020-06-16       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.